Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation
Open Access
- 11 March 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 1 (3) , 154-156
- https://doi.org/10.1093/ndtplus/sfn013
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndromeAnnals of Oncology, 2007
- Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and BevacizumabJNCI Journal of the National Cancer Institute, 2007
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinomaNature Clinical Practice Nephrology, 2007
- Thrombotic microangiopathy and anti-VEGF agentsNephrology Dialysis Transplantation, 2007
- Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2006
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006
- Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUSPediatric Nephrology, 2004
- Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces ProteinuriaJournal of Biological Chemistry, 2003
- Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathyKidney International, 2000